Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT04520529

Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas

Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age> 18 years old
  • Informed consent signed by the patient
  • Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria

Exclusion criteria

  • Patient under guardianship or curatorship
  • Lack of affiliation to social security

Treatment and study plan

Biologic Samples

Other
  • An additional punch from lesion skin as part of a skin biopsy performed as part of routine care.
  • an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care.
  • In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.

Primary outcomes

  1. overall survival

    Time frame: 5 years

Secondary outcomes

  1. Progression free survival

    Time frame: 5 years

  2. Progression free survival

    Time frame: 10 years

  3. Overall survival

    Time frame: 10 years

Study contacts

Contact information is provided by the study sponsor or research team.

Adèle DE MASSON

CONTACT

[email protected]

01 42 49 43 19

Matthieu RESCHE-RIGON

CONTACT

[email protected]

0142499742 ext. 0142499742

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: LYMPHOTEQ

Important dates

Study start
2020
Primary completion
2045
Study completion
2050
First posted
Aug 20, 2020
Registry last updated
Aug 20, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.